The EMA's decision is a blow to
Shares in German drugs and chemicals group Merck have fallen after European regulators refused approval for a new multiple sclerosis (MS) treatment.
Merck shares fell 10% on Friday after the European Medicines Agency (EMA) said the benefits of Merck's cladribine drug did not outweigh the risks.
On Wednesday, rival drugmaker Novartis won backing in US for its own MS pill.
Merck said it was considering its next step, and did not rule out an appeal against the EMA's decision.
The company expects a decision from the US Food and Drug Administration over a marketing approval for cladribine later this year.
But the EMA's decision is seen as a blow to Merck in the race for a slice of the huge US market for MS treatment.
Tells feds to move forward on registry, clinical trials
- Jill Whitford underwent the controversial “MS liberation” surgery in Mexico in June, and says she feels great. (WINNIPEG SUN)
Jill Whitford thinks Canada’s health minister is wrong.
Whitford, a resident of St. Georges, underwent the controversial “MS liberation” surgery in Mexico in June, and says she feels great. She also feels the government is doing multiple sclerosis patients a great disservice by accepting the recommendation of the Canadian Institutes of Health Research to delay clinical trials on the controversial procedure until more information is available.
“The people with MS are the experts. Ask me,” Whitford said. “This is my life. I will go wherever I have to go to get my life back so I don’t have to feel (sick). Who are you to tell me when I can start feeling better?”
Whitford was diagnosed with MS 28 years ago. Last year she heard about a new procedure that uses angioplasty to open up veins to increase the flow of blood draining from the brain. An Italian doctor has linked the procedure to improvements in MS patients, but his work has been criticized by many.